Stable Disease

Imatinib interruption should not be considered for patients with advanced gastrointestinal stromal tumor who do not have progressive disease, according to results of a randomized phase 3 trial.

Each month, John Sweetenham, MD, and I review a stack of reports from conferences and the international literature for reporting in HemOnc Today.